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Abstract: Certain viruses have the ability to subvert the mammalian immune response, including
interference in the chemokine system. Poxviruses produce the chemokine binding protein vCCI
(viral CC chemokine inhibitor; also called 35K), which tightly binds to CC chemokines. To facilitate
the study of vCCI, we first provide a protocol to produce folded vCCI from Escherichia coli (E. coli.)
It is shown here that vCCI binds with unusually high affinity to viral Macrophage Inflammatory
Protein-II (vMIP-II), a chemokine analog produced by the virus, human herpesvirus 8 (HHV-8).
Fluorescence anisotropy was used to investigate the vCCI:vMIP-II complex and shows that vCCI
binds to vMIP-II with a higher affinity than most other chemokines, having a Kd of 0.06 ± 0.006 nM.
Nuclear magnetic resonance (NMR) chemical shift perturbation experiments indicate that key amino
acids used for binding in the complex are similar to those found in previous work. Molecular
dynamics were then used to compare the vCCI:vMIP-II complex with the known vCCI:Macrophage
Inflammatory Protein-1β/CC-Chemokine Ligand 4 (MIP-1β/CCL4) complex. The simulations show
key interactions, such as those between E143 and D75 in vCCI/35K and R18 in vMIP-II. Further, in a
comparison of 1 µs molecular dynamics (MD) trajectories, vMIP-II shows more overall surface binding
to vCCI than does the chemokine MIP-1β. vMIP-II maintains unique contacts at its N-terminus to
vCCI that are not made by MIP-1β, and vMIP-II also makes more contacts with the vCCI flexible acidic
loop (located between the second and third beta strands) than does MIP-1β. These studies provide
evidence for the basis of the tight vCCI:vMIP-II interaction while elucidating the vCCI:MIP-1β
interaction, and allow insight into the structure of proteins that are capable of broadly subverting the
mammalian immune system.
Keywords: chemokine binding protein; chemokine analog; anti-inflammation; 35K; vCCI; vMIP-II;
MIP-1β/CCL4; molecular dynamics
1. Introduction
Protein–protein interactions are critical for many aspects of biological and immunological function.
Of particular interest are virally-encoded proteins that undermine the immune system, often by
having the ability to promiscuously bind many targets, and therefore, help the virus evade immune
surveillance. One such system targeted by viruses is the chemokine system, in which virally encoded
proteins disrupt the chemokine receptor/ligand interaction [1]. Chemokines (chemotactic cytokines)
are a class of small secreted proteins that mediate immune cell chemotaxis as part of the inflammatory
response. There are about 18 human chemokine receptors that are activated upon binding to their
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cognate chemokine ligand [2]. About 50 chemokine ligands are known, spanning 4 sub-families.
The two major subfamilies are CC chemokines (named for the adjacent Cys near the N-terminus of the
protein) and CXC chemokines (named for having an intervening amino acid between the conserved
N-terminal Cys). In general, CC chemokines (named numerically as CCL1; chemokine ligand 1,
etc.) bind to and activate cognate receptors on the surfaces of monocytes, macrophages and T-cells,
and these receptors are numerically named as CC receptors (e.g., CCR1, CCR2). CXC chemokines tend
to have cognate receptors on the surface of neutrophils [2], with receptors such as CXCR1. Chemokines
can sometimes bind multiple receptors, and receptors often have more than one cognate ligand,
although CC chemokines are restricted to CC chemokine receptors, and CXC chemokines have their
own CXC receptors.
Because of the central nature of the chemokine system in activating and localizing immune
cells, subversion of the process may be useful to a virus. Several types of chemokine-binding
proteins (CKBPs) have been identified (reviewed in [3]), including those that bind chemokines from
multiple subfamilies, such as Myxoma-T7 (M-T7) from myxoma [4], M3 from γ-herpesvirus-68 [5–8],
and the poxvirus-encoded smallpox virus-encoded chemokine receptor (SECRET) domain [9].
These proteins have gained interest as inflammation inhibitors, due to their ability to bind to
pro-inflammatory proteins.
One of the most potent inhibitors of chemokine action is the poxvirus-encoded protein vCCI
(viral CC chemokine inhibitor; also called 35K). This approximately 240 amino acid protein binds
80 CC-chemokines across several species, about 20 of which have nanomolar affinity to this
inhibitor [10,11]. The protein sequence across several poxviruses shows high identity, and the
structures from cowpox [12], rabbitpox [13], and mousepox [14] reveal a beta sandwich with a binding
face containing several key negatively charged amino acids, as well as a long acidic loop between beta
strands 2 and 3. We have carried out structural studies of vCCI in complex with MIP-1β (also called
CCL4 [13]), which revealed details of the interaction between vCCI and the chemokine, including
several close contacts that are critical for binding. Mutagenesis of vCCI/35K by others, in vitro and
in vivo, has confirmed the importance of several of the residues suggested by the structure, including
E143 and the acidic loop [14,15]. Mutagenesis studies on the chemokines themselves have also been
carried out by us and others and indicate that several evolutionarily conserved, positively charged
residues are important for binding to vCCI/35K [11,16,17]. In our work, with a variety of eotaxin
mutants (CCL11 [11]), we showed that eotaxin’s binding to vCCI was dependent on the presence of
several basic residues in the chemokine.
Viruses have also evolved the ability to interfere with the chemokine system by producing
chemokine homologs, small proteins that mimic the chemokine’s ability to bind a chemokine receptor,
thus blocking the native chemokine. Herpesvirus HHV-8 encodes several such chemokine analogs;
of particular interest is the protein vMIP-II (virally encoded macrophage inflammatory protein-II),
which has about 40% identity with the human CC chemokine MIP-1β, and has been shown to bind
and antagonize several CC chemokine receptors (CCR1, CCR2, CCR5, though it can agonize CCR3
and CCR8), as well as at least one CXC receptor (CXCR4) [18–20]. This range of receptor binding is
much greater than a typical chemokine. We have previously studied vMIP-II to elucidate its ability to
bind glycosaminoglycans, and have shown that, in solution, it is a soluble monomer with a fold similar
to that of MIP-1β [21,22]. Due to its nanomolar affinity to, and broad ability to bind to chemokine
receptors [18,22], vMIP-II has engendered interest as an anti-inflammatory agent, with some success in
rat studies involving ischemic stroke [23], spinal cord injury [24], and kidney transplant rejection [25].
vCCI and vMIP-II are therefore complementary proteins, the former having evolved to bind a
large variety of CC chemokines, and the latter having evolved to be a prototypical chemokine ligand
with the ability to bind many receptors. While we have studied these proteins in complex with their
natural ligands [11,13,22,26], we developed the hypothesis that a significant amount of insight could
be obtained by determining whether a tight complex could be formed by these proteins. In other
words, we set out to study the complex between an “ideal” chemokine binding protein (vCCI) and an
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“ideal” chemokine homolog (vMIP-II). Due to the broad action of these proteins, an understanding of
these powerful viral tools may be helpful in designing strategies to manipulate or control immune
responses, and could be applicable to fields ranging from autoimmunity to traumatic brain injury.
We present a technique for producing rabbitpox vCCI from Escherichia coli (E. coli.), as well as
experimental and molecular dynamics analysis of the vCCI:vMIP-II complex and the vCCI:MIP-1β
complex, comparing these two complexes to explore the differences in binding between the
virus-encoded chemokine analog and a natural human chemokine [13]. Our results show that the
affinity of vCCI to vMIP-II is higher than that between vCCI and natural chemokines [11,18] and
suggest explanations for this high affinity, as well as for previously-reported functional results.
2. Results
2.1. Folded Viral CC Chemokine Inhibitor(vCCI)/35K Can Be Produced from E. coli
Despite interest in the mechanism of affinity of vCCI, and for its possible use as a therapeutic,
it has been relatively time consuming to produce in vitro, since bacterial expression results in unfolded
protein. High expression of proteins from this family have been described from yeast [11–13],
baculovirus [14,17], and an antibody fragment crystallizable region(Fc)-linked vCCI was produced
from 293T mammalian cells [15]. Each technique is useful, but the lack of an E. coli expression protocol
has limited study of the protein, and in particular, limited the ability of investigators to easily make a
wide range of mutants. We have expressed vCCI from E. coli, and show that the protein can successfully
be refolded. Briefly, the cells are disrupted in 6 M guanidine hydrochloride at pH 8.0 under reducing
conditions, and purified with a nickel chelating column. After further reducing agent is added,
the solution is slowly added to 20× volume of a cold refold buffer containing L-arginine, sucrose,
and glutathione, and incubated for 1 day. The solution is then dialyzed at pH 7.4, followed by addition
of a protease to allow cleavage of the fusion tag. Final purification is carried out on an anion-exchange
column (see Materials and Methods for details).
The final product of refolding and purification results in a 15N heteronuclear single quantum
coherence (HSQC) spectrum of vCCI/35K that is essentially identical to that produced from
Pichia pastoris yeast expression (Figure 1A and Figure S1). Further, this protein forms a complex
upon addition of chemokine analog vMIP-II (Figure 1B), showing its functionality.
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Figure 1. (A) 1H-15N heteronuclear single quantum coherence (HSQC) spectrum of unbound 15N-
labeled vCCI in 100 mM NaCl, 20 mM NaOP (sodium phosphate) pH 7.0, measured at 37 °C; (B) 
Overlay of the 1H-15N HSQC spectra of free 15N-labeled viral CC chemokine inhibitor (vCCI) (black) 
and 15N vCCI:14N vMIP-II (red) with a ratio of 1:3, measured under the same conditions as in (A). The 
concentration of vCCI was 50–60 μM. 
Figure 1. (A) 1H-15N heteronuclear single quantum coherence (HSQC) spectrum of unbound
15N-labeled vCCI in 100 mM NaCl, 20 mM NaOP (sodium phosphate) pH 7.0, measured at 37 ◦C;
(B) Overlay of the 1H-15N HSQC spectra of free 15N-labeled viral CC chemokine inhibitor (vCCI)
(black) and 15N vCCI:14N vMIP-II (red) with a ratio of 1:3, measured under the same conditions as in
(A). The concentration of vCCI was 50–60 µM.
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2.2. vCCI:vMIP-II Produce a High Affinity Complex
vCCI has a remarkable ability to bind almost all chemokines from the CC subfamily, and a
qualitative measure of its binding with herpesvirus encoded vMIP-II has been reported [10]. To more
quantitatively investigate the affinity between vCCI and vMIP-II, we used isothermal titration
calorimetry, in which vMIP-II was titrated into a solution of vCCI. This technique can provide several
thermodynamic parameters, and often a dissociation constant. Analysis of the titration data indicated
that the Kd of the complex was below 1 × 10−10 M (Table S1). This is the lowest detectable limit of the
instrument, and so an alternate method was used to obtain a more accurate binding constant.
An alternative method of obtaining affinity involves a competition technique in which vCCI is
bound to a fluorescently labeled chemokine (eotaxin-1/CCL11), and the competitor (vMIP-II in this
case) is titrated into the solution, with the resulting change in fluorescence anisotropy providing the
dissociation constant for the interaction [11]. This showed a Kd of 0.06± 0.006 nM for the vCCI:vMIP-II
interaction (Figure 2). This is among the tightest measured vCCI:chemokine interactions.
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Figure 2. Co petition fluorescence anisotropy of the v CI:vMIP-II interaction. vMIP-II was added
to a complex of vCCI with fluorescently labeled eotaxin-1 (CCL11) as in [11]. Error bars are shown,
but are so etimes within the size of the data point.
2.3. Changes in Chemical Shift Suggest vCCI:vMIP-II Interaction Is Similar to Other vCCI:Chemokine Complexes
To determine the amino acids that are likely involved in the vCCI:vMIP-II complex, a comparison
of chemical shift changes between the free and bound forms of both vCCI/35K and vMIP-II was
carried out. In the case of vCCI, 15N HSQC spectra in the free and bound form using 15N labeled
vCCI (with non-isotopically labeled vMIP-II) were measured and compared, to determine the level
of peak movement upon complex formation. (Assignments of the unbound vCCI were obtained
from [27] and Biological Magnetic Resonance Bank (BMRB) databank 6809.) Chemical shift changes
in the 15N vMIP-II HSQC spectrum upon binding non-isotopically labeled vCCI/35K were also
determined. In cases where unambiguous assignment of the peak in the bound spectrum was
not possible, conservative assessments of peak movements were made, indicating that actual peak
movement could be greater than shown. Figure 3 shows residue-by-residue chemical shift change.
See Table 1 for definitions of chemical shift perturbation categories.
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Figure 3. Changes in chemical shift upon complex formation. (A) Changes in chemical shift in vCCI
upon binding to vMIP-II. Arrows represent beta strands while spiral lines represent alpha helices.
See Table 1 for definitions of “0”, “1”, “2”, “3”; (B) Structure showing changes in vCCI (Protein Data
Bank code 2FFK upon binding vMIP-II. Green indicates greater than average, up to 1 standard deviation
away from the average; yellow indicates over 1 standard deviation away from the average; red indicates
below one standard deviatio or the peak ha not been discernable; (C) Changes in chemical shift
in vMIP-II upon binding to vCCI. Secondary structure is shown by arrows and spiral lines, as in (A).
See Table 1 for definitions f “0”, “1”, “2”, “3”; (D) Structure showing those changes in vMIP-II upon
binding vCCI (Protei Data Bank code 1VMP). Gree indicates greater than average, up to 1 standard
deviation away from the average; yellow indicates over 1 standard deviation away from the average;
blue indicates below one standard deviation or the peak had not been discernable. All structure
figures were prepared by using UCSF Chimera (UCSF Resource for Biocomputing, Visualization,
and Informatics, San Francisco, CA, USA) [28].
Table 1. Definitions of the chemical shift perturbation categories in Figure 3.
Chemical Shift
Perturbation Definition vCCI Chemical Shift
vMIP-II Chemical
Shift
0 No confirmable change No peaks visible No peaks visible
1 Less than or equal to average ∆δobs ≤ 0.045 ∆δobs ≤ 0.100
2
Greater than average, up to one
standard deviation above
average
0.045 < ∆δobs ≤ 0.086 0.100 < ∆δobs ≤ 0.178
3 Greater than one standarddeviation above average ∆δobs ≥ 0.086 ∆δobs ≥ 0.178
∆δobs: the difference in chemical shift between bound and free form of 15N-labeled complexes, as defined
in Methods.
As shown in Figure 3A, the areas of greatest chemical shift change for vCCI/35K upon binding to
vMIP-II are located in the region of amino acids in the 80’s, 140’s, and 190’s, with changes also observed
in the 30’s, 170’s–180’s and 220’s. These areas are shown on the structure of vCCI/35K (shown without
vMIP-II) in Figure 3B, and indicate a binding surface similar to those shown previously [11,13,14,27],
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comprised of negative charges (D141, E143, as well as likely the negatively charged loop in the 52–77
region that is not clearly assignable, likely due to flexibility) as well as interaction in the early 80’s
region. Figure 3C indicates that vMIP-II interacts with vCCI/35K using residues from its N-loop region
(residues 12–19), and with the second beta strand in the 30’s region, as well as with residues in the
early 50’s. Figure 3D shows vMIP-II with presumed interacting regions highlighted.
2.4. Molecular Dynamics Simulations on vCCI:vMIP-II
To further clarify the structural components and the likely interacting surfaces of the complex, and
to gain insight into the extraordinarily tight binding between vCCI/35K and vMIP-II, we carried out
molecular dynamics (MD) simulations to create 1 microsecond (µs) trajectories of both the vCCI:MIP-1β
complex and the vCCI:vMIP-II complex. Both trajectories are based on the reported vCCI:MIP-1β
structure (Protein Data Bank (PDB) ID: 2FFK), but for MIP-1β, the residues were changed to reflect
the wild type chemokine, as opposed to the triple mutant used in that structure determination [13].
The vCCI:vMIP-II trajectory was created from the same complex structure, but by computationally
superimposing the vMIP-II structure onto the MIP-1β chain to minimize the average difference between
the corresponding Cα backbone atoms ([13]; Figure 4A,B and Figure S2). (A third simulation was also
included that used the 2FFK structure directly, keeping MIP-1β as a triple mutant (K45A/R46A/K48A)
instead of changing it to wild type. However, this third simulation is not emphasized in this work; see
the Materials and Methods section for more details on the simulations.)
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at least 50% of the time, and that are within 2.8 Å of the partner residue on the other protein in at least 
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Figure 4. Complexes after 1 µs molecular dynamics simulation of vCCI:chemokine. For all figures,
vCCI is in red ribbon, and the bound chemokine is either blu ribbon (vMIP-II) or green ribbon
(MIP-1β). (A) Structure of vCCI:vMIP-II after 1 µs trajectory; (B) Structure of vC I:MIP-1β in complex
after 1 µs trajectory; (C) Interactions bet een residues of vCCI and vMIP-II, as well as vCCI and
MIP-1β. Hydrogen bonds (solid lines) are shown if they appear in at least 50% of the last 300 ns of
the molecular dynamics simulation. Dashed lines indicate non-hydrogen-bond interactions between
residues. These are defined as residues whose access to solvent is occluded upon complex formation at
least 50% of the time, and that are within 2.8 Å of the partner residue on the other protein in at least
50% of the structures sampled every 20 ns for the final 500 ns of the trajectory.
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Analysis of the secondary structure of the complexes during the trajectory shows that all of the
α-helices and β-sheets are preserved though out the 1 microsecond runs for all three complexes (see
Figure S3). The root-mean-square deviation (RMSD) in the position of the backbone Cα atoms for
the entire complex is less than 1 nm over the entire runs and the RMSD for the individual vCCI
and MIP-1β chains is less than 0.8 nm, indicating no gross protein disordering over the simulation,
although there are highly flexible regions in both the vCCI and the chemokines. The residue-level
fluctuations (RMSF) are the root-mean square fluctuations of each residue around the average protein
structure for a trajectory. The RMSF values plotted vs sequence location and calculated for the final
750 ns of the trajectories are shown in Figure S4. These show significant fluctuations of the vCCI
N-terminal residues in all three complexes, as well as in the vCCI loop at residues 52–77. As described
below, the loop acts as an “arm” that folds down on the bound chemokine. The MIP-1β structures
show significant fluctuations at both the N- and C-termini, while vMIP-II shows fewer fluctuations at
its termini.
Figure 5 plots the total number of interstrand (vCCI:chemokine) hydrogen bonds over the
1 microsecond simulation for each of the three complexes. The vCCI:vMIP-II complex has significantly
more interstrand hydrogen bonds than either of the MIP-1β complexes while the wild type MIP-1β
has more than the mutant. Figure 4C shows the hydrogen bonds formed in the vCCI complex with
both vMIP-II and MIP-1β.
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for the final 500 nanoseconds of the simulation, for a total of 51 structures analyzed per complex.
The three complexes show different total amounts of buried surface area, as shown in Table 2.
Additionally, specific residue–residue contacts vary between the three different complexes. Figure S5
shows interactions of residues that are occluded during the simulation upon complex formation at
least 50% of the time, and that are within 2.8 Å of the partner residue in at least 50% of the structures
sampled every 20 ns for the final 500 ns of the trajectory.
Table 2. Buried surface area between vCCI and chemokine variants averaged over 51 structures
analyzed during the final 500 ns of simulation.
Complex vCCI Buried Surface Area (Å2) Chemokine Buried Surface Area (Å2)
vCCI:vMIP-II 1473 1528
vCCI:MIP-1β wild type 1355 1392
vCCI:MIP-1β K45A/R46A/K48A
(variant used in 2FFK structure
determination)
1020 1060
A comparison of the dynamics trajectories of vCCI/35K binding to vMIP-II and to MIP-1β shows
some striking differences, in particular, revealing several possible interactions that may account for the
approximately 10-fold tighter binding for vMIP-II to vCCI/35K. First, at the end of the simulation, the
total buried surface area for vMIP-II in complex is 1528 Å2, while the buried surface area for MIP-1β in
complex is 1392 Å2. Second, as shown in Figures 5 and 4C, during the time course of the trajectory,
vCCI/35K shows an overall larger number of hydrogen bonds with vMIP-II than with MIP-1β. Third,
the flexible, negatively charged loop in the 52–77 region of vCCI (between beta strands 2 and 3)
makes more contact, including a larger number of hydrogen bonds over the course of the trajectory,
with vMIP-II than with MIP-1β. And finally, during the 1 µs trajectory, vMIP-II shows overall more
interactions with vCCI than does MIP-1β, in particular, at the N-terminus of the chemokine where a
large portion of that region of vMIP-II lays across the vCCI binding face, while the MIP-1β N-terminus
does not.
The vCCI:vMIP-II trajectory shows several individual interactions that illuminate aspects of
their binding and complementary interactions, including significant contact throughout the trajectory
between residues E143 on vCCI/35K and residue R18 in vMIP-II (Figure 6A); and interaction between
the negatively charged loop between strands β2 and β3 in vCCI/35K with K45/R46 in vMIP-II
(Figure 6C). A similar trajectory is seen for vCCI:MIP-1β, with MIP-1β residue R18 showing interactions
with E143, as well as D141 of vCCI (Figure 6B). However, vMIP-II’s R18 residue also shows interaction
with vCCI residue D75 for almost half the time steps in the trajectory, while no such interaction is
observed with MIP-1β. The trajectories also show both vMIP-II and MIP-1β have their 24/45/46
position residues clustered together, and interacting with the vCCI loop between β2 and β3, but
the interaction is much more extensive in the vCCI:vMIP-II complex (Figure 6C,D and Figure 4C).
The N-terminus of each of the chemokines also behaves very differently in the trajectory. vMIP-II
shows considerably more interaction with vCCI throughout its N-terminus for much of the trajectory,
while the MIP-1β trajectory shows an N-terminus that does not appear to interact consistently with
vCCI, with main contacts to the binding partner not starting until residue 8. In total, the simulation
results point to possible reasons why vCCI shows different binding constants to various partners.
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3. Discussion
The ability to modulate the immune system, and in particular, to reduce the inflammatory
response, has great potential in health and medicine. Protein therapeutics have been approved for
this purpose [32,33], and investigation has continued into other potential sources of anti-inflammatory
proteins. Both herpesviruses and poxviruses have evolved to produce proteins that subvert the
mammalian che okine system, and these include both chemokine binding proteins as well as
chemokine homologs [3,34,35]. The current work investigates the unusually high affinity interaction
between the vCCI/35K chemokine binding protein from rabbitpox, and vMIP-II, a chemokine analog
from herpesvirus HHV-8, with a combination of biophysical and molecular dynamics techniques.
vCCI was successfully produced and purified from E. coli. This fairly efficient procedure will
greatly expand the range of experiments that can be carried out with vCCI, from quickly making large
quantities of the protein (and any desired variants) for X-ray crystallography, to inexpensive isotopic
labeling that can lead to a variety of NMR experiments, including a full structure determination.
Isothermal titration calorimetry indicated a high affinity for the vCCI:vMIP-II complex, and this was
confir ed by fluorescence anisotropy, which revealed a Kd of 0.06 nM ± 0.006 nM that is significantly
lower than the Kd observed for vCCI with other chemokines using the same method [11]. Other
groups have investigated the binding constant of vCCI with various chemokines using other methods,
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including early qualitative work that suggested that vCCI/35K bound vMIP-II more tightly than most
other chemokines [10]. Others have used a scintillation proximity assay [35] and surface plasmon
resonance [14,16,17] to show that vCCI/35K binds a variety of chemokines at levels ranging from
sub-nanomolar to 20 nM.
Analysis of chemical shift perturbation by NMR indicates that vCCI/35K interacts with vMIP-II
using residues similar to those that have been shown to be important in binding by vCCI to other
chemokines, MIP-1β/CCL4, and eotaxin-1/CCL11 [11,13], such as acidic residues in the 141/143
area. Similarly, chemical shift perturbation of vMIP-II upon binding vCCI/35K shows chemical shift
changes in generally known areas, including the region near R18, as well as the area near the so-called
N-loop of the chemokine, where hydrophobic L13 is located (Figure 3). While NMR chemical shift
perturbation is a powerful tool, there are two main drawbacks. First, while a perturbation suggests
a locus for protein–protein interaction, and one can infer regions of interaction between proteins,
it does not confirm a pairwise interaction with the binding partner. Second, 2D 15N HSQC spectra
can be ambiguous in terms of assigning peaks upon movement. To resolve ambiguity would require
13C-labeling of the protein(s) and a series of 3D NMR experiments [11]. Therefore, we chose to
pursue molecular dynamics simulations, which provide a high resolution “movie” (within certain
approximations) of the structure and motions of all atoms in the protein and surrounding solvent,
and can delineate specific interactions and provide insight into differences in affinity.
Atomistic classical molecular dynamics (MD) is a well-established tool for studying protein
structure and dynamics [36]. In typical protein MD, the motions of all atoms are simulated using
empirical force fields that approximate the forces due to bonded and non-bonded interactions.
The resulting output is a high-resolution series of atomic motions that can be analyzed to characterize
the structure and dynamics of the protein, and infer the energy causes of the observed behavior.
With modern computers and MD software, it is feasible to routinely run simulations of moderately
large proteins (including a solvation shell of water and ions) for microsecond timescales, with the
largest published MD simulations reaching millisecond times [37]. The accuracy is limited by the
approximate nature of the force field and the limitation that bonds are not broken or formed during the
simulations (including protonation and deprotonation of acid and base sites), but MD has been shown
able to accurately predict protein properties, such as the folded conformation of small proteins [38].
In the investigation of the vCCI:vMIP-II complex, a 1 µs MD trajectory was run, providing great
insight into likely interactions that were not observable and/or confirmable by our NMR experiments
to this point. In general, the hypothesis that these two viral proteins may be a near-ideal binding pair
is supported by the MD trajectories, which show that that vCCI:vMIP-II complex has a larger buried
surface area (including the vMIP-II’s N-terminus) and a greater number of hydrogen bonds throughout
the trajectory, including more interactions between the chemokine and the negatively charged flexible
loop of vCCI than the vCCI:MIP-1β complex. The MD simulations also provide context for specific
regions of interaction that may be useful in general for a vCCI:chemokine complex. For example,
D141 and E143 in vCCI were observed to contact R18 in the vCCI:MIP-1β structure [13], and this
R18 was found to be critical for vCCI/35K binding in other chemokines [11,13,16,17]. However,
mutational studies on vCCI/35K showed E143 to be more important than D141 [15]. The MD trajectory
provides an explanation, showing significant, continuous interaction between E143 (vCCI/35K) and
R18 (vMIP-II), while almost no close interaction across the trajectory is observed with D141. In the
vCCI:MIP-1β trajectory, significant hydrogen bonding interaction (although below the 50% threshold
for Figure 4C) is observed between R18 of the chemokine and both E143 and D141 of vCCI, although
the interaction with E143 predominates.
The MD trajectory also provides a possible explanation for other unexplained mutational results.
In the original structure of the complex between vCCI/35K and MIP-1β /CCL4, it was observed
that both Y80 and R89 in vCCI/35K appeared close in space to the 48th position of MIP-1β [13].
In many chemokines, this position contains a large, basic residue that could be expected to both
sterically and electrostatically clash with those groups. It had been noted that mutation of this
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residue to the smaller Ala48 increased affinity for a similar chemokine MCP-1/CCL2 [16,17]. Indeed,
MIP-1β was mutated from a Lys to an Ala at that position in the structure, and that mutation was
attributed to tighter binding to vCCI. In an attempt to design a vCCI/35K that was better able to bind
chemokines, White et al. mutated each Y80 and R89 to Ala in vaccinia vCCI/35K, hypothesizing that
a smaller, uncharged residue in these positions would better interact with the large basic residue of
a chemokine [15]. Interestingly, while the vCCI/35K R89A mutation did lead to a better chemokine
binding ability, Y80A completely abolished the activity of the protein. The MD trajectory of Y80 in the
vCCI:MIP-1β complex shows the tyrosine side chain of vCCI consistently forming a hydrogen bond
with the backbone nitrogen of Lys48 of MIP-1β (Figures 4C and 7B). This Y80 hydrogen bond was not
consistently observed in the vCCI:vMIP-II trajectory, although the trajectory shows consistent contact
between these residues (Figure S5). In either case, the Y80 in this crowded area of the protein shows
little motion and appears to be holding open the negatively charged loop in vCCI. The Y80 residue in
vCCI has also been mutated by Arnold et al., who replaced tyrosine with arginine. This mutation did
also lead to loss of chemokine binding ability, although in this case, the cause is likely placing a basic
Arg on vCCI near the Arg48 of a chemokine [14].
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subvert the mammalian immune system, and an understanding of their interaction will be useful in
both their development as possible therapeutics and in general protein design for immunomodulation.
4. Materials and Methods
4.1. Protein Purification
4.1.1. Purifying vCCI from E. coli
The gene sequence encoding the rabbit pox vCCI was slightly modified by PCR to allow for proper
cleavage by enterokinase, which does not cut efficiently near proline. DNA coding for Met-Pro in the
first two amino acids was replaced with DNA coding for Ala-Met-Ala. The resulting gene was cloned
into the pET32a vector utilizing the restriction sites NcoI and HindIII. The plasmid was transformed
into E. coli BL21 (DE3) (Novagen, Madison, WI, USA) competent cells and expressed in Luria broth or
minimal media with 15NH4Cl as the sole nitrogen source. Protein production was induced when the
absorbance at 600 nm reached 0.70–0.75 with the addition of isopropyl β-D-1-thiogalactopyranoside
(IPTG) to 1mM and incubated with shaking at 22 ◦C for 20 h. The cells were then harvested by
centrifugation at 4200× g, 4 ◦C for 12 min and supernatant was discarded.
The cell pellet was resuspended in 6 M guanidine hydrochloride, 200 mM NaCl, and 50 mM Tris
(pH 8.0) and was lysed by three passages through a French press and then centrifuged at 27,000× g for
1 h. The supernatant was decanted and 15 mM β-mercaptoethanol (β-ME) was added and allowed to
stir at room temperature for 2 hours to reduce. The solution was then loaded onto a nickel chelating
column (Qiagen, Hilden, Germany) equilibrated with the resuspension buffer containing 15 mM βME
after a thorough 0.3 M imidazole wash to remove unbound nickel. The column containing the bound
vCCI was washed with 10 column volumes of resuspension buffer containing 15 mM βME, and then
with 10 column volumes of wash buffer (6 M Guanidinium chloride, 200 mM NaCl, 15 mM βME,
80 mM NaOP, pH 7.2). Proteins were eluted from the column using 6 M guanidine hydrochloride,
200 mM NaCl, and 60 mM NaOAc, pH 4. Fractions containing the eluted protein were identified by
absorbance at 280 nm and then pooled together. βME was then added to a concentration of 25 mM.
The fractions were allowed to stir for one hour at room temperature, followed by stirring for 12 hours
at 4 ◦C overnight.
The protein was then refolded by dropwise addition to 20x volume of ice-cold refolding buffer
(9.6 mM NaCl, 0.4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 550 mM L-arginine hydrochloride, 400 mM
sucrose, 3 mM reduced glutathione (GSH), 0.3 mM oxidized glutathione (GSSG), 50 mM Tris, pH 8),
and then allowed to stir 24 h at 4 ◦C. The solution was dialyzed 4 times into 4 liters 200 mM NaCl,
2 mM CaCl2, 20 mM Tris, pH 7.4 buffer at 4 ◦C.
To cleave the thioredoxin fusion tag from the purified protein, the samples were incubated for
12 hours at 4 ◦C with 650 nM of the protease enterokinase. The samples were then dialyzed 4 times
into 4 L of 20 mM Bis-Tris, 50 mM NaCl pH 7.1 and then passed through a 0.2 µm nylon filter to then be
purified on a HiTrap™ Q HP Column (GE Healthcare Life Sciences, Chicago, IL, USA) using a gradient
from 50 mM NaCl, 20 mM Bis-Tris pH 7.1 to 1 M NaCl, 20 mM Bis-Tris pH 7.1, to separate the cleaved
tag from vCCI. The fractions were analyzed on an SDS-PAGE gel to confirm purity and then fractions
containing vCCI were concentrated using the Amicon concentrators (Millipore, Billerica, MA, USA),
and buffer was changed to 100 mM NaCl, 20 mM NaOP pH 7.0 with 0.02% NaN3 for NMR studies.
4.1.2. Expression and Purification of vMIP-II
The gene for vMIP-II was placed into a pET28 vector and transformed into Escherichia coli BL21
(DE3) (Novagen, Madison, WI, USA) competent cells and expressed in either minimal media with
15NH4Cl as the sole nitrogen source for 15N-labeled samples or Luria Broth for 14N-labeled samples.
Protein production was induced by adding IPTG to 1 mM and incubated with shaking at 37 ◦C for 5 h.
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The cell pellet was resuspended in 6 M guanidine hydrochloride, 200 mM NaCl, 10 mM
benzamidine, 50 mM Tris (pH 8.0) and were lysed by French press and then centrifuged at 27,000× g
for 1 h. The soluble portion was then loaded onto a nickel chelating column (Qiagen, Hilden, Germany)
equilibrated with the resuspension buffer. Proteins were eluted from the column using a pH gradient
with 6 M guanidine hydrochloride, 200 mM NaCl, 60 mM NaOAc (pH 4) followed by addition of
10 mM βME while stirring for 2 hours at room temperature. The proteins were then refolded by
dropwise addition into 10× volume of refolding buffer (550 mM L-arginine hydrochloride, 200 mM
NaCl, 1 mM EDTA (Ethylenediaminetetraacetic acid), 1 mM reduced glutathione (GSH), 0.1 mM
oxidized glutathione (GSSG), 50 mM Tris, pH 8), and then allowed to stir overnight at 4 ◦C. The solution
was dialyzed three times into 4 L of 200 mM NaCl, 20 mM Tris pH 8 buffer at 4 ◦C.
To cleave the Small Ubiquitin-like Modifier (SUMO) fusion tag from the purified protein,
the samples were incubated for 12 hours with 100 nM of the Ubl-specific protease 1 (ULP-1). The protein
solution was then centrifuged to remove precipitated material and added onto a second nickel chelating
column (Qiagen, Hilden, Germany), with flow-through containing the cleaved vMIP-II being collected.
The samples were then dialyzed and purified on a C4 reversed-phase chromatography column (Vydac,
Hesperia, CA, USA), using an acetonitrile gradient. The fractions were analyzed on an sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel to confirm purity and lyophilized in a
Labconco freeze-dry system.
The proteases used in these purifications were produced and purified in our laboratory as briefly
described: ULP1 or enterokinase protease were proteins were expressed in LB medium using a pET-28b
vector and the cells were collected and French pressed. The ULP1 protease from the supernatant
was purified using a nickel chelating column [39]. The enterokinase was found in the inclusion
body and resuspended in 6M guanidinium buffer before being purified using a nickel chelating
column. Enterokinase was then dialyzed in buffer to allow for refolding and tested for activity through
self-cleavage of the fusion tag (manuscript in preparation).
Proteins used in fluorescence anisotropy studies were purified as specified in [11]. vCCI for these
experiments were made using a gene encoding rabbitpox virus vCCI cloned into pPIC9K plasmid and
then transformed into Pichia pastoris strain SMD1168 (Invitrogen, Carlsbad, CA, USA) and purified as
previously described [13].
4.2. Nuclear Magnetic Resonance (NMR) Spectroscopy
All NMR samples were made in 20 mM sodium phosphate buffer, 100 mM NaCl with 10% D2O,
5 µM 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS), and 0.02% NaN3, with a final pH of 7.0. 15N
labeled lyophilized vMIP-II was resuspended into 5 mM NaOP buffer, pH 2.8 in order to dissolve the
protein, and then 10 µL was added to 340 µL NMR buffer (either alone or with 150 uM 14N-vCCI) for
final vMIP-II concentration of 50-60 µM. 14N-vMIP-II was also resuspended into 5 mM NaOP, pH 2.8,
and 10 µL was added to 340 µL NMR buffer containing 15N-labeled vCCI, for a final concentration
of 150 µM VMIP-II in the sample. vCCI was exchanged into NMR buffer as explained in the above
sections, with final concentrations for 15N samples being 50–60 µM.
All HSQC NMR data were acquired on a four-channel 600 MHz Bruker Avance III spectrometer
(Bruker Corp, Billerica, MA) equipped with a (GRASP II) gradient accessory and a (TCI) cryoprobe
with an actively shielded Z-gradient coil. Spectra with 15N-labeled vMIP-II were measured at 25 ◦C;
spectra with 15N-labeled vCCI were measured at 37 ◦C. The chemical shift was referenced relative
to internal DSS [40]. The data were processed using NMRPipe [41] and analyzed using PIPP [42]
(Available online: https://spin.niddk.nih.gov/bax/software/NMRPipe/). For HSQC spectra, sweep
width = 8474.576(1H) and 1766.784 Hz (15N), with 1280 points in 1H and 128* (256 total) points in 15N.
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The weighted average chemical shift change of the 1H and 15N resonances for each residue upon
binding was calculated using the equation [43]:
∆δobs =
√√√√∆δH2 + (∆δN5 )2
2
(1)
where ∆δH and ∆δN are the chemical shift changes of the 1H and 15N dimensions, respectively. Here,
the ∆δobs is the difference between bound and free form of 15N-labeled complexes. Due to lack of
13C labeling, some bound peak identifications were estimates; to be conservative, the nearest residue
without a clear origin were assumed to belong to the residues in question.
4.3. Isothermal Titration Calorimetry (ITC)
A Nano ITC Low Volume isothermal titration calorimeter (TA Instruments, New Castle, DE, USA)
was loaded with degassed 10 uM vCCI in 20 mM NaOP, 100 mM NaCl, pH 7.0 and water in the reference
cell. Twenty 2.5 µL injections of 100 µM vMIP-II also in 20 mM NaOP, 100 mM NaCl, pH 7.0 were then
injected at 300 second intervals, with a 350 rpm stirring speed. Baseline selection, buffer-into-buffer
blank was subtracted from the data, and peak-by-peak manual integration was performed using
NanoAnalyze software (TA Instruments, New Castle, DE, USA). The data for an independent binding
site model was provided by the software. The Kd was below detectable limits (10−10 nM).
4.4. Fluorescence Anisotropy
Fluorescence anisotropy experiments were carried out in three independent experiments as
described in [11], at 25 ◦C and pH of 7.0 utilizing a Photon Counting (PC1) spectrofluorimeter and
VINCI software (ISS, Champaign, IL, USA), with an excitation wavelength of 497 nm and emission
wavelength of 524 nm. The obtained data were then fit to a system of mass conservation equations as
well as the following equation:
θ =
[L] f ree × Ka
1 + [L] f ree × Ka
(2)
where θ is the fraction of bound eotaxin-K63C, [L]free is the concentration of unbound vCCI, and Ka is
the association constant for the complex.
For the competitive binding experiment, a 1:1 ratio of the vCCI:eotaxin-K63C (both proteins were
prepared and purified as described in [11], with eotaxin-K63C labeled with fluorescein-5-maleimide)
complex was prepared at a concentration of 8 nM. 500 µL of this complex was then mixed with
varying amounts of unlabeled vMIP-II and incubated 30 minutes at 25 ◦C. Anisotropy measurements
were taken and the values were normalized so that 1 represents the 100% bound state. The resulting
data were fit using Scientist software (Micromath, Salt Lake City, UT, USA) to a system of equations
described previously [44,45].
4.5. Molecular Dynamics
All-atom molecular dynamics was performed on three vCCI:MIP complexes. All three complex
structures were based on the NMR structure of the VCCI:MIP-1β complex (PDB: 2FFK), which has
three mutations from the wild type MIP-1β sequence. We recreated the original wild type structure by
in silico editing of the 2FFK experimental structure. The vCCI:vMIP-II starting structure was created
from the vCCI:MIP-1β structure by computationally superimposing the experimental vMIP structure
(PDB code 1VMP) on the MIP-1β chain, to minimize the average difference between the corresponding
Cα backbone atoms (see Figure S2). The net charge (−11 vCCI:vMIP-II, −26 vCCI:MIP-1β mutant,
−23 vCCI:MIP-1β wild type) on the complexes was neutralized by adding Na+ ions and additional
Na+/Cl− pairs (~60) were added to yield an ion concentration of approximately 70 millimolar. After
short equilibration runs, a full 1 microsecond of MD simulation was run using Gromacs 5.0.7 [46–48]
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using the NPT ensemble, the Verlet cutoff scheme and a 2 fs timestep. All bonds to hydrogen were
constrained to their equilibrium length using the LINCS algorithm [49]. Temperature was maintained
at 300K using the Bussi et al. thermostat [50] and pressure at 1 bar using the Parrinello-Rahman
barostat [51]. The simulations were performed using the AMBER99SB-ILDN force field for the
protein [52] and the TIP3P water model [53].
4.6. Figure Preparation
All structure figures were prepared by using UCSF Chimera (UCSF Resource for Biocomputing,
Visualization, and Informatics, San Francisco, CA, USA) [28].
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/8/1778/s1.
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Abbreviations
vCCI Viral CC Chemokine Inhibitor; also called 35K or vCCI/35K
vMIP-II Viral macrophage inflammatory protein II
E. coli Escherichia coli
NMR Nuclear magnetic resonance
HSQC Heteronuclear single quantum coherence
NaOP Sodium phosphate
HHV-8 Human herpesvirus 8, Kaposi’s sarcoma-associated herpesvirus
MIP-1β Macrophage inflammatory protein β, also known as CCL4
CCL4 CC chemokine ligand 4, also known as MIP-1β
IPTG Isopropyl β-D-1-thiogalactopyranoside
DSS 4,4-dimethyl-4-silapentane-1-sulfonic acid
β-ME β-mercaptoethanol
RMSD Root mean squared deviation
RMSF Root mean squared fluctuation (for specific residues)
MD Molecular dynamics
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